BioSpace News Archive

BioCryst Pharmaceuticals, Inc. announced that the Institut national d’excellence en santé et services sociaux has issued a positive recommendation for PrORLADEYO® to be reimbursed for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years of age and older in Quebec.

Acepodia today announced that Nobel Laureate Carolyn Bertozzi, Ph.D., was recently appointed Chief Scientific Advisor.

Factorial Biotechnologies and Ginkgo Bioworks today announced a new collaboration.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announces the launch of MAVERICK.

ContraFect Corporation today announces that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on September 15, 2023.

Accuray Incorporated announced that the company has opened the doors of its new global training facility, the Accuray Center for Education, located at its corporate headquarters in Madison, Wisconsin.

Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard) announces today that it has selected its lead candidate for MDG2011, a T cell receptor engineered T cell (TCR-T) therapy targeting KRAS (Kirsten rat sarcoma viral oncogene homologue) G12V with HLA-A*11 and being developed in combination with the Company’s PD1-41BB costimulatory switch protein (CSP) technology.

Alpha Teknova, Inc. announced that it has entered into definitive agreements for the issuance and sale of an aggregate of up to 1,086,485 of its shares of common stock in a registered direct offering at a purchase price of $1.85 per share.

Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX) today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the Catalyst’s senior management team, will participate in the 2023 Cantor Global Healthcare Conference which will be held on September 26-28, 2023.

CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) supplement to permit the expansion of the study of the eShunt System.